A groundbreaking international clinical trial has delivered one of the most significant advances in cancer treatment this decade. Researchers reported that a personalized mRNA vaccine developed for individual melanoma patients reduced the risk of cancer recurrence or death by 42% when used alongside immunotherapy. Unlike traditional treatments, the vaccine is custom-built using the patient’s own tumor mutations, helping the immune system recognize and destroy remaining cancer cells. Medical experts describe the results as a major step toward a new era of personalized oncology.
About the Author
